|
Biocryst Pharmaceuticals, Inc. (BCRX) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
BioCryst Pharmaceuticals, Inc. (BCRX) Bundle
¡Obtenga información sobre su análisis de valoración de BioCryst Pharmaceuticals, Inc. (BCRX) con nuestra calculadora DCF de vanguardia! Precedidos con datos reales (BCRX), esta plantilla de Excel le permite ajustar los pronósticos y supuestos para determinar con precisión el valor intrínseco de BioCryst.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 48.8 | 17.8 | 157.2 | 270.8 | 331.4 | 440.1 | 584.4 | 776.0 | 1,030.4 | 1,368.3 |
| Revenue Growth, % | 0 | -63.53 | 782.38 | 72.31 | 22.37 | 32.79 | 32.79 | 32.79 | 32.79 | 32.79 |
| EBITDA | -96.3 | -167.6 | -121.7 | -143.9 | -116.3 | -321.9 | -427.4 | -567.5 | -753.6 | -1,000.7 |
| EBITDA, % | -197.16 | -940.74 | -77.46 | -53.12 | -35.1 | -73.14 | -73.14 | -73.14 | -73.14 | -73.14 |
| Depreciation | .7 | .7 | .8 | 1.4 | 1.7 | 6.3 | 8.4 | 11.2 | 14.9 | 19.7 |
| Depreciation, % | 1.48 | 4.2 | 0.49437 | 0.5306 | 0.49938 | 1.44 | 1.44 | 1.44 | 1.44 | 1.44 |
| EBIT | -97.0 | -168.3 | -122.5 | -145.3 | -118.0 | -323.2 | -429.2 | -569.9 | -756.8 | -1,004.9 |
| EBIT, % | -198.64 | -944.94 | -77.95 | -53.65 | -35.6 | -73.44 | -73.44 | -73.44 | -73.44 | -73.44 |
| Total Cash | 136.2 | 300.4 | 514.4 | 442.4 | 389.0 | 440.1 | 584.4 | 776.0 | 1,030.4 | 1,368.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 22.1 | 8.6 | 29.4 | 50.6 | 57.0 | 130.7 | 173.5 | 230.4 | 306.0 | 406.3 |
| Account Receivables, % | 45.35 | 48.54 | 18.71 | 18.68 | 17.18 | 29.69 | 29.69 | 29.69 | 29.69 | 29.69 |
| Inventories | 1.6 | 7.0 | 15.8 | 27.5 | 28.7 | 63.0 | 83.6 | 111.1 | 147.5 | 195.8 |
| Inventories, % | 3.18 | 39.52 | 10.05 | 10.17 | 8.65 | 14.31 | 14.31 | 14.31 | 14.31 | 14.31 |
| Accounts Payable | 14.0 | 18.7 | 27.8 | 14.4 | 20.9 | 139.0 | 184.6 | 245.1 | 325.5 | 432.2 |
| Accounts Payable, % | 28.64 | 105.06 | 17.69 | 5.3 | 6.3 | 31.59 | 31.59 | 31.59 | 31.59 | 31.59 |
| Capital Expenditure | -.3 | -.5 | -2.4 | -1.4 | -2.2 | -5.5 | -7.3 | -9.7 | -12.9 | -17.1 |
| Capital Expenditure, % | -0.70237 | -2.89 | -1.52 | -0.49884 | -0.65417 | -1.25 | -1.25 | -1.25 | -1.25 | -1.25 |
| Tax Rate, % | -0.13703 | -0.13703 | -0.13703 | -0.13703 | -0.13703 | -0.13703 | -0.13703 | -0.13703 | -0.13703 | -0.13703 |
| EBITAT | -107.0 | -181.0 | -124.0 | -146.9 | -118.2 | -323.2 | -429.2 | -569.9 | -756.8 | -1,004.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -116.3 | -168.0 | -146.1 | -193.2 | -119.6 | -312.3 | -446.0 | -592.2 | -786.4 | -1,044.3 |
| WACC, % | 13.14 | 13.14 | 13.14 | 13.14 | 13.14 | 13.14 | 13.14 | 13.14 | 13.14 | 13.14 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2,076.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1,065 | |||||||||
| Terminal Value | -9,564 | |||||||||
| Present Terminal Value | -5,160 | |||||||||
| Enterprise Value | -7,236 | |||||||||
| Net Debt | 715 | |||||||||
| Equity Value | -7,951 | |||||||||
| Diluted Shares Outstanding, MM | 192 | |||||||||
| Equity Value Per Share | -41.37 |
What You Will Get
- Real BCRX Financials: Access to both historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Evaluate various scenarios to assess BioCryst's future performance.
- User-Friendly Design: Designed for industry professionals while remaining approachable for newcomers.
Key Features
- 🔍 Real-Life BCRX Financials: Pre-filled historical and projected data for BioCryst Pharmaceuticals, Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate BioCryst’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize BioCryst’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file for BioCryst Pharmaceuticals, Inc. (BCRX).
- Step 2: Review the pre-entered data for BioCryst (historical and projected).
- Step 3: Adjust key assumptions (highlighted in yellow) based on your analysis.
- Step 4: Observe the automatic recalculations for BioCryst's intrinsic value.
- Step 5: Utilize the outputs for your investment decisions or reporting needs.
Why Choose BioCryst Pharmaceuticals, Inc. (BCRX)?
- Innovative Solutions: Pioneering treatments that address unmet medical needs in rare diseases.
- Proven Expertise: A team of seasoned professionals dedicated to advancing pharmaceutical science.
- Commitment to Quality: Rigorous testing and development processes ensure high standards in our products.
- Patient-Centric Approach: Focused on improving patient outcomes and enhancing quality of life.
- Strong Pipeline: A robust portfolio of drug candidates that promise future growth and value.
Who Should Use BioCryst Pharmaceuticals, Inc. (BCRX)?
- Pharmaceutical Students: Understand drug development processes and apply them to real-world case studies.
- Researchers: Utilize innovative models in your studies related to rare diseases and treatments.
- Investors: Evaluate your investment strategies and analyze the market potential of BioCryst's pipeline.
- Healthcare Analysts: Enhance your analysis with a tailored approach to assessing biotech companies.
- Medical Professionals: Learn how pharmaceutical companies like BioCryst are shaping the future of treatments.
What the Template Contains
- Pre-Filled Data: Includes BioCryst Pharmaceuticals’ historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze BioCryst Pharmaceuticals’ profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.